Read more
1:07 PM · 14 December 2020

AstraZeneca stock fell 6% on $39-billion Alexion bill

AstraZeneca (AZN.UK) stock dropped more than 6% after the pharma giant announced on Saturday it would buy US drugmaker Alexion Pharmaceuticals (ALXN.US) and its line of treatments for rare diseases for $39 billion in its largest ever deal. The offer would provide a 45% premium to Alexion’s closing price on Friday. It’s the largest deal for AstraZeneca since it was founded in a 1999 combination of British and Swedish companies, and would entrench its position among the world’s 10 biggest drugmakers. The purchase is “an important step in the history of the company,” CEO Pascal Soriot said on a call with reporters. “It’s a tremendous opportunity for us to accelerate our development of immunological” therapies.
AstraZeneca's (AZN.UK) shares fell as much as 9.2% and touched their lowest level since April. However buyers managed to halt declines at 74.22 level and price bounced off. Currently stock is testing resistance at  77.67 which previously acted as a support. If buyers manage to break above it, an upward impulse towards major resistance at 82.20 could be launched. This level is additionally strengthened by 50 SMA (green line) and 200 SMA (red line). On the other hand, failure to break higher could see the stock pull back towards aforementioned support at 74.22 area. Source: xStation5
11 May 2026, 2:39 PM

US OPEN: Semiconductors keep the market at record highs

11 May 2026, 2:12 PM

The market is getting ahead of Intel’s actual results.

8 May 2026, 5:43 PM

Microsoft: Hedge Fund Sharply Cuts Position and Warns About AI Risks

8 May 2026, 4:34 PM

Cloudflare: strong results, weak outlook, and a painful market reaction

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits